Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors
about
Resistance to integrase inhibitors.Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.Role of raltegravir in the management of HIV-1 infection.GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1.Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.Analysis of transmitted resistance to raltegravir and selective pressure among HIV-1-infected patients on a failing HAART in Sao Paulo, Brazil.In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors.Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.HIV-host interactome revealed directly from infected cells.HIV resistance to raltegravirIntegrase residues that determine nucleotide preferences at sites of HIV-1 integration: implications for the mechanism of target DNA binding.Novel integrase inhibitors for HIV.Primary resistance to integrase strand-transfer inhibitors in Europe.HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.Different Pathways Leading to Integrase Inhibitors ResistanceCharacterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.Sequential deletion of the integrase (Gag-Pol) carboxyl terminus reveals distinct phenotypic classes of defective HIV-1.Prospective strategies for targeting HIV-1 integrase function.HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil.Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.Absence of HIV-1 drug resistance mutations supports the use of dolutegravir in Uganda.Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan.Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco.
P2860
Q34059896-D923711A-9266-4B8F-8DB5-091B48634B1CQ34108775-A1AC1FD2-7C21-4557-92E4-1DDD5F823D0AQ34520239-EE432F11-B60B-4484-9599-8E40A1CFEE80Q34737411-F8951335-88E6-4F7F-BB8B-E9EB120D1A40Q35134947-FC337298-AC81-43A4-98FD-03CA0608DEFFQ35148034-9B587730-A884-4C78-AD26-E44ED31EF0CDQ35557318-BD352E37-5F49-4BC8-A919-49129ACE47FEQ35629509-A2603E51-2032-4ADA-B91B-4DA441DFE30FQ35694729-00DFF820-B2BD-4589-B993-55BB64A72B41Q35789343-8F6F18AB-131A-4E38-BFF1-B3C4D802FA1EQ36022923-4A76A938-9590-46A6-AE40-80DFECDA47A7Q36099861-8FA1E691-8DD7-4CA7-AF0C-A906625F35FCQ36155580-C652C111-0B88-4183-A490-7413847F2E51Q36284159-52D3D209-9836-4BC0-8860-140666B5737CQ36839676-71C22543-5519-4E46-AD16-ACDBCCFFBA11Q37055800-395313A2-8E66-48BC-A207-F18C4782D0F3Q37644128-E1CCF8E8-4EC9-4096-8620-34DD2872D465Q37734406-544B8853-BBE9-40A1-9453-71FFA61DAC7CQ37779774-8715924B-A7A4-4CAD-87C7-92718852199CQ38424195-9001CD78-0BB6-407F-AA24-24A6DFDDA867Q38599565-72093357-CEFD-4D61-A64E-F061C2BD4969Q39103603-B10FC1A4-C6A6-4540-A016-C4FB5C917010Q39421000-F3E7C657-172A-4F8B-A9DB-DE4854A80A6BQ39582953-C14B83BB-1389-4CD1-9DFE-74F1452C6912Q39777687-B9862E9D-5921-4936-844F-67F1371EE992Q41238955-83D168C9-9814-4510-9D21-D41F2D7E6937Q41884057-9D547F20-88A0-4AAF-B2AD-066B137216E8Q42276732-379621CF-B1CF-41E9-A789-D0F08EA23120Q42917410-B97194BF-1B57-4C9D-B98F-001750973013Q45501766-F749EE8C-709A-47C7-BD06-89F01B7BB52DQ45924259-D1F272B0-E912-414E-99D5-865E851B620EQ46307515-2E049D72-8D3E-476F-B06B-5DE200C96B86Q47130258-E9CE4D08-C732-45DC-A594-9BB4255F5D9AQ47558450-D13AB6F8-F925-4462-BC62-5C53624D4391Q48066731-2DEDE2A9-EC53-49C2-8DEA-CF3B1BB179D6Q55060074-C5CE38B1-D248-46A7-A8CE-A6371A23E036Q55446383-424CAE11-B1B9-4D4B-9F96-72F4F53188A2
P2860
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Natural polymorphisms of human ...... panel of integrase inhibitors
@en
Natural polymorphisms of human ...... panel of integrase inhibitors.
@nl
type
label
Natural polymorphisms of human ...... panel of integrase inhibitors
@en
Natural polymorphisms of human ...... panel of integrase inhibitors.
@nl
prefLabel
Natural polymorphisms of human ...... panel of integrase inhibitors
@en
Natural polymorphisms of human ...... panel of integrase inhibitors.
@nl
P2093
P2860
P356
P1476
Natural polymorphisms of human ...... panel of integrase inhibitors
@en
P2093
Andrea Low
Daria Hazuda
Florin Vaida
Hiroshi Mohri
Mark Muesing
Martin Markowitz
Michael Topper
Nicole Prada
P2860
P304
P356
10.1128/AAC.00397-09
P407
P577
2009-08-03T00:00:00Z